Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $22.01 million. The enterprise value is $13.80 million.
| Market Cap | 22.01M |
| Enterprise Value | 13.80M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 10.87 million shares outstanding. The number of shares has increased by 96.17% in one year.
| Current Share Class | 10.87M |
| Shares Outstanding | 10.87M |
| Shares Change (YoY) | +96.17% |
| Shares Change (QoQ) | +83.83% |
| Owned by Insiders (%) | 5.14% |
| Owned by Institutions (%) | 14.31% |
| Float | 7.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.38 |
| Forward PS | 0.32 |
| PB Ratio | 0.62 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 6.77 |
| P/OCF Ratio | 6.71 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 4.24 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.51.
| Current Ratio | 1.13 |
| Quick Ratio | 0.90 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | 5.57 |
| Interest Coverage | -4.39 |
Financial Efficiency
Return on equity (ROE) is -52.55% and return on invested capital (ROIC) is -28.46%.
| Return on Equity (ROE) | -52.55% |
| Return on Assets (ROA) | -4.54% |
| Return on Invested Capital (ROIC) | -28.46% |
| Return on Capital Employed (ROCE) | -16.52% |
| Weighted Average Cost of Capital (WACC) | 6.60% |
| Revenue Per Employee | $757,500 |
| Profits Per Employee | -$187,526 |
| Employee Count | 76 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Aytu BioPharma has paid $21,000 in taxes.
| Income Tax | 21,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.56% in the last 52 weeks. The beta is 0.18, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -14.56% |
| 50-Day Moving Average | 2.21 |
| 200-Day Moving Average | 2.37 |
| Relative Strength Index (RSI) | 38.62 |
| Average Volume (20 Days) | 49,901 |
Short Selling Information
The latest short interest is 311,607, so 2.87% of the outstanding shares have been sold short.
| Short Interest | 311,607 |
| Short Previous Month | 334,399 |
| Short % of Shares Out | 2.87% |
| Short % of Float | 4.05% |
| Short Ratio (days to cover) | 12.06 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $57.57 million and -$14.25 million in losses. Loss per share was -$1.16.
| Revenue | 57.57M |
| Gross Profit | 36.82M |
| Operating Income | -8.32M |
| Pretax Income | -14.23M |
| Net Income | -14.25M |
| EBITDA | -4.39M |
| EBIT | -8.32M |
| Loss Per Share | -$1.16 |
Balance Sheet
The company has $26.31 million in cash and $18.11 million in debt, with a net cash position of $8.20 million or $0.75 per share.
| Cash & Cash Equivalents | 26.31M |
| Total Debt | 18.11M |
| Net Cash | 8.20M |
| Net Cash Per Share | $0.75 |
| Equity (Book Value) | 35.27M |
| Book Value Per Share | 3.29 |
| Working Capital | 7.10M |
Cash Flow
In the last 12 months, operating cash flow was $3.28 million and capital expenditures -$29,000, giving a free cash flow of $3.25 million.
| Operating Cash Flow | 3.28M |
| Capital Expenditures | -29,000 |
| Depreciation & Amortization | 3.93M |
| Net Borrowing | -4.85M |
| Free Cash Flow | 3.25M |
| FCF Per Share | $0.30 |
Margins
Gross margin is 63.95%, with operating and profit margins of -14.44% and -24.76%.
| Gross Margin | 63.95% |
| Operating Margin | -14.44% |
| Pretax Margin | -24.72% |
| Profit Margin | -24.76% |
| EBITDA Margin | -7.62% |
| EBIT Margin | -14.44% |
| FCF Margin | 5.65% |
Dividends & Yields
Aytu BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -96.17% |
| Shareholder Yield | -96.17% |
| Earnings Yield | -64.77% |
| FCF Yield | 14.78% |
Analyst Forecast
The average price target for Aytu BioPharma is $9.50, which is 369.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.50 |
| Price Target Difference | 369.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 26.39% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Aytu BioPharma has an Altman Z-Score of -4.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.06 |
| Piotroski F-Score | 3 |